Lil­ly's mirik­izum­ab, once a con­tender for pso­ri­a­sis, bol­sters case for UC in­di­ca­tion in main­te­nance tri­al da­ta read­out

Ear­ly last year, Eli Lil­ly an­nounced that in­stead of tak­ing its block­buster con­tender mirik­izum­ab for­ward to the FDA for pso­ri­a­sis, it would be es­sen­tial­ly go­ing nowhere in the in­di­ca­tion. In­stead, the phar­ma then an­nounced in its Q1 ’21 earn­ings state­ment that it would be fo­cus­ing on ul­cer­a­tive col­i­tis and Crohn’s dis­ease in­di­ca­tions in a sud­den about-face.

And as the drug is be­fore the FDA for po­ten­tial ap­proval for the first in­di­ca­tion of ul­cer­a­tive col­i­tis, the megaphar­ma is now ready to re­veal more da­ta to bol­ster its case.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER